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Carotid atherosclerosis: where we have been and where we are going 
Abstract 
Objective While carotid atherosclerosis (CA) biomarkers are valuable surrogates for 
cardiovascular events, a significant gap exists between predicted and actual event rates. 
Recent advances in carotid plaque imaging may have a transformative impact on this issue. 
We performed an interdisciplinary systematic review and bibliometric analysis to understand 
the future role of CA in cardiovascular diseases (CVDs) prevention. 
Methods We applied a comprehensive search strategy to construct a representative dataset of 
the bibliographic records of CA from 1997 to 2017. A total of 31793 retrieved articles and 
407473 cited references were included in the analysis. The co-word network and co-citation 
network were derived to describe the intellectual structure of CA. Milestones detected by 
burst analysis were reviewed to delineate the dynamic patterns of CA. Interdisciplinary 
studies detected by structural variation analysis were used to help understand the emerging 
trends of CA. 
Results CA is a multidisciplinary field of study that could be divided into three communities 
concerning the early prevention of subclinical atherosclerosis, revascularization of carotid 
stenosis and imaging techniques. A specialty in CA may go through three stages: the 
exploration stage, the verification stage and the calibration stage. Carotid plaque imaging had 
become a converging trend in pathology, epidemiology and clinical practice of CA. 
Conclusions The role of CA in CVDs prevention is now undergoing a paradigm shift from 
“luminal narrowing” to “vulnerable plaques”. An advanced treatment and evaluation system 
based on a series of carotid plaque imaging techniques is establishing. 
Keywords: carotid atherosclerosis, carotid intimal-medial thickness, carotid plaque, carotid 
stenosis, bibliometric analysis
 1. Introduction 
Carotid atherosclerosis (CA) is a chronic vascular disease with a narrowing of the carotid 
artery walls caused by atherosclerotic lesion formation1. About 10-15% of all strokes follow 
thromboembolism from a previously asymptomatic carotid artery stenosis >50%2. This 
relation has promoted the use of CA biomarkers to aid the best individually tailored 
preventive strategy for cardiovascular events. 
The most widely used CA biomarker in the past two decades is carotid artery stenosis. A 
fundamental role of carotid stenosis severity is established in stroke risk and indication of 
clinical intervention by current guidelines3,4. However, recent studies have highlighted its 
inadequacy in identifying high-risk groups among asymptomatic patients, given the 
uncertainty of net benefits based on this classification system5,6. Another widely adopted CA 
biomarker is carotid intimal-medial thickness (cIMT). Under the tacit assumption that we 
could prevent cardiovascular diseases (CVDs) by intervening subclinical atherosclerosis, 
cIMT was included as a surrogate in pharmacotherapy trials. But a growing body of evidence 
proved that cIMT is only a mild reclassification modifier at best and interventions including 
cIMT as a primary outcome to indicate cardiovascular risk might be “inherently 
misleading”7,8. 
On the contrary, noninvasive imaging of carotid plaques has experienced a prosperity in 
the past decade. Emerging evidence shows that the characterization of the carotid plaque by 
various methods are stroke risk factors independent of stenosis severity9,10. It is believed that 
we are now undergoing a paradigm shift towards a new era of plaque-based risk 
stratifications driven by imaging technologies11. However, studies using novel carotid plaque 
imaging markers to predict patient outcome are relatively small and scattered. A 
comprehensive interdisciplinary review is needed to understand the past and future role of 
CA in the prevention of CVDs. 
Previous reviews have been methodologically limited to relatively small ranges, which 
makes it difficult to identify the scientific changes hidden in the process of interdisciplinary 
interaction. Recent advances in scientometrics and bibliometrics have made it possible to deal 
with a large amount of literature simultaneously, so as to clearly reveal the hidden patterns of 
disciplinary evolution, and therefore, to provide a quantitative visualization method for trend 
prediction. The purpose of this study is to identify the past and the future role of CA in the 
prevention of CVDs with visualized bibliometric analysis. 
2. Method 
2.1 Data collection 
We searched the Web of Science with “Carotid” AND (“atherosclerosis” OR “thick*” OR 
“plaque” OR “stenosis”) on 22 February 2018 to include publications related to “Carotid 
atherosclerosis”, “Carotid artery atherosclerosis”, “Carotid intima-media thickness”, “Carotid 
wall thickness”, “Carotid wall thickening” “Carotid plaque”, “Carotid atherosclerotic 
plaque”, “Carotid stenosis” or “Carotid artery stenosis”. We included original articles and 
reviews in English, published between Jan 1, 1997 and Dec 31, 2017. This query generated 
31,793 records with 407,473 valid references, which accounted for 99.34% of all cited 
references and was considered generic enough to be applicable to a science mapping study. 
2.2 Visualization and Analysis 
We used co-word analysis to summarize the major disciplines related to CA. Top 8 subject 
categories in each year from 1997 to 2017 were used to generate a co-word network. 
Pathfinder network scaling, which retains the most significant connections, was used to 
simplify the subject category network. Co-word frequency and betweenness centrality of the 
categories were used to describe the connections between different disciplines. 
We used co-citation analysis to identify the major topics in CA. Top 100 most cited 
references in each year from 1997 to 2017 were selected to generate a progressively 
synthesized co-citation network, which was then divided into co-citation clusters. Each 
cluster represented the intellectual base of a certain topic. We used two visualization 
techniques - the landscape view and the timeline view - to show the relationship and temporal 
characteristics of co-citation clusters. Each node in the network represented a highly cited 
reference. The co-citation relations between nodes were represented by colored curves. Top-
ranked keywords by Log-likelihood ratio test method were selected as cluster labels12. 
We used burst analysis to detect the milestones in the major topics. Burst detection is a 
computational technique that has been used to identify abrupt changes of events13. This 
technique is based on the number of citations a reference received in the corresponding year 
of publication14. The shift of fast-increasing citation indicates the evolution history of active 
areas. The burst strength and duration of references were used as a valuable indicator of the 
most active research topics. The article with the strongest burst strength in a cluster is the 
landmark of a research topic. We summarized the research designs, topics and conclusions of 
burst references to reveal the evolution history of the major topics. 
We used structural variation analysis (SVA), in addition to citation-based patterns, to 
detect the interdisciplinary studies of CA in recent years. According to the theory of structural 
variation, the transformative potential of an article may be reflected by the extent to which it 
varies the existing intellectual structure15. SVA could identify the extraordinary connections 
across clusters made by certain articles. We summarized the articles with transformative 
potentials between 2012 and 2017. 
We visualize and analyze the dataset with CiteSpace V. Figure 1 shows the overview of 
the analytic framework. 
3. Result 
3.1 Intellectual structure of CA 
Figure 2 shows the subject category co-word network with 14 frequent categories from 1997 
to 2017 in CA. The most common category in CA was “Cardiovascular system & 
Cardiology”, followed by “Peripheral Vascular Disease”. “Neurosciences & Neurology”, 
“Medicine, Research & Experimental”, “Radiology, Nuclear Medicine & Medical Imaging” 
and “Endocrinology & Metabolism” had high degree of centrality, which means these 
categories tend to bridge different subareas of CA. 
Figure 3 shows the timeline view of the co-citation network, which contains 853 cited 
references published from 1989 to 2016. The network had a modularity of 0.778, suggesting 
that the topics in CA were clearly defined. This map shows the main research branches of CA 
with 11 significantly aggregated co-citation clusters. Table 1 shows the size, temporal 
characteristics and main themes of each cluster. The largest cluster (#0) included 132 nodes, 
which accounted for 15.47% of the network. The top 11 largest clusters accounted for 
77.84% of the entire network. The average silhouette score of these major clusters was 0.921, 
suggesting a high level of homogeneity. The most enduring cluster spanned 25 years, while 
the shortest cluster lasted only 10 years. Clusters that were still active include #2, #4, #5, #8 
and #9. Figure 4 shows the landscape view of the co-citation network. The 11 clusters could 
be divided into three communities according to their spatial clustering the relevance of 
themes:  
 Community 1, which consists of #0, #2, #6 and #8, focused on the early prevention 
of subclinical atherosclerosis. 
 Community 2, including #1, #3, and #4, focused on the revascularization of carotid 
stenosis and its comparation with medical therapies 
 Community 3, including #5, #7, #9, and #11, showed the most commonly used 
imaging techniques in CA. 
3.2 Evolution history of CA 
A total of 472 burst references were detected, of which 87.08% belonged to the 11 major 
clusters. Table 2 shows the distribution of burst references in the major clusters. The strongest 
burst article appeared in cluster #0, and Cluster #4 had the highest average burst strength 
(51.21). 
3.2.1 Community 1 – Early prevention of subclinical atherosclerosis 
Clusters in Community 1 covered 3 specialties related to the early prevention of subclinical 
atherosclerosis, including cIMT (#0 and #2), inflammation of atherosclerosis (#6) and artery 
stiffness (#8). We will particularly focuse on the first specialty and give a brief introduction to 
inflammation of atherosclerosis, given their relevance with CA. 
Cluster #0 & #2 - Carotid intima–media thickness 
Cluster #0 and #2 depicted the evolution history of research on cIMT, the most concerned 
imaging biomarker of CA in the past two decades. Cluster #0 revealed the early history, while 
#2 showed the latest developments. 
Cluster #0 was the largest cluster, containing 132 references across a 17-year period from 
1989 to 2005. This cluster could be divided into two stages according to the 89 burst 
references detected. Figure 5 shows the top 5 burst references in each stage. 
In the first stage (1989-1996), population-based cross-sectional and case-control studies 
accounted for the majority of burst references. A variety of ultrasonic measurement methods 
of wall thickness in the carotid artery, including the common carotid artery, carotid 
bifurcation and inner carotid artery, were developed and applied16-25. The morphological 
characteristics, population distribution, determinants and the association with CVDs of 
carotid artery wall thickness were found26-37. Pharmaceutical studies started to use the 
imaging indicators of carotid artery wall thickness as the basis for evaluation38-46.  
In the second stage (1997-2005), cohort studies began to dominate. Ultrasonic measured 
cIMT became known as a noninvasive marker for atherosclerosis, a powerful predictor and a 
potential risk reclassification tool of CVDs47. The most influential studies in this cluster 
demonstrated the association between increases in cIMT and increased risk of myocardial 
infarction, stroke or coronary heart disease48-56. Therapeutic trials showed that overall statins 
and antihypertensive drugs may have a beneficial effect on cIMT progression and reduce the 
incidence of cardiovascular events57-64. 
Cluster #2 was the largest currently active cluster, containing 75 references across a 14-
year period from 2002 till 2015. More than fifty burst references were detected in this cluster, 
including 20 cohort studies, 12 systematic reviews and 9 consensus or guidelines. The 
perception of the relationship between cIMT and CVDs was further deepened and solidified 
in this cluster. The year 2008 seemed to be a turning point to this perception. On the one 
hand, the strongest burst reference in this cluster showed that cIMT is a strong predictor of 
future vascular events65. The predictive value of cIMT on future vascular events was further 
confirmed in the younger population66. On the other hand, however, cIMT had been proved 
only a mild reclassification modifier in head to head comparation with other biomarkers since 
2008, which made its clinical utility open to question8,67-75. 
The shift in the perception of cIMT could also be observed by the development of 
guidelines, consensuses and pathological studies76-82. The latest “European Guidelines on 
cardiovascular disease prevention in clinical practice (version 2016)” downgraded the 
recommendation for cIMT screening from “should be considered (Class IIa/B)” to “not 
recommended (Class III/A)”3,79. The only burst pathological article in cluster #2, published in 
2010 by Finn AV, specifically pointed out the limitations of cIMT and the potential of plaque 
in cardiovascular risk assessment7. In the end of this cluster, the greater incremental value of 
measures that include plaque area and thickness, rather than cIMT alone, received 
considerable attention83-87. 
The application of cIMT in pharmacology seemed less controversial. The progression of 
cIMT had long been accepted a surrogate for CVDs endpoints in statin trials88. After the 
efficacy and safety of statin therapy were confirmed by systematic reviews89,90, the combined 
medication of statins with other drugs, such as torcetrapib, ezetimibe or niacin, became the 
next focus between 2008 and 201291-93. In the last few years, the clinical application of statins 
had expanded to populations such as low-risk individuals with subclinical atherosclerosis94 
and apparently healthy persons without hyperlipidemia but with elevated C-reactive protein95. 
Cluster #6 - Inflammation in atherosclerosis 
Cluster #6 revealed the early history of inflammation research in atherosclerosis. This cluster 
contained 48 references across a 14-year period from 1992 till 2005. At first, it was 
discovered that inflammation related factors, such as chlamydia pneumoniae infection, serum 
antibodies and circulating adhesion molecules, were associated with CA or coronary heart 
disease96-105. A fundamental role was then established for inflammation in mediating 
atherosclerosis by basic science and epidemiological studies106-112. In the end of this cluster, 
the incremental value of inflammatory markers, including C-reactive protein, fibrinogen, 
serum antibodies, cytokines and soluble adhesion molecules, became the major focus. As a 
summery, a statement suggested to limit the assays of inflammatory markers to 
hypersensitive C-reactive protein, given their stability, consistency and predictive abilities113. 
But it was also pointed out that inflammatory markers might still be able to measure the 
characteristics of plaques. 
3.2.2 Community 2 – Revascularization of carotid artery stenosis 
Cluster #1, #3 and #4 showed the development and competition history of carotid 
endarterectomy (CEA) and carotid angioplasty and stenting (CAS). Custer #1 showed the 
early history of evaluation and technological development of CAS, while Cluster #3 focuses 
on the efficiency evaluation of CEA for a wider population, especially patients with 
asymptomatic carotid stenosis. A series of studies comparing these two techniques were 
presented in Cluster #4. The top 25 strongest burst references showed the major milestones in 
Community 2 (Table 3). 
Cluster #1 - Carotid angioplasty and stenting 
Cluster #1 was the second largest cluster with 91 cited references that covered a 19-year 
duration from 1990 to 2008. This cluster could be divided into two stages according to the 51 
burst reference detected. Figure 6 shows the top 5 burst references in each stage. 
The first stage (1990-2000) mainly consisted of nonrandomized or non-controlled trials, 
evaluating the feasibility, safety, and efficacy of CAS in the treatment of carotid artery 
occlusive disease. Refinement techniques for high-risk patient identification and embolic 
complications elimination were developed114-117. CAS became a potential alternative to CEA, 
especially for patients with severe medical comorbidity or recurrent carotid artery stenosis 
following CEA118-129. However, a randomized trial of CEA vs CAS was stopped primarily 
because of problems with informed consent130. CAS generated widely divergent opinions 
about its therapeutic role and called for results from randomized trials131. 
The second stage (2001-2008) appeared several high-impact contributions, including 5 
randomized controlled trials132-136. The strongest burst reference in this cluster reported a 
similar effectiveness between CAS and CEA among patients with severe carotid-artery 
stenosis135. A Cochrane systematic review also found no significant difference in the major 
risks between these two treatments137. Short and long-term effectiveness of embolic 
protection devices were evaluated138-143, and the preoperative identification of carotid 
ulceration and thrombus became the next emphasis in high-risk patient identification144,145. 
However, in the end of this cluster, a competitive result attracted wide attention that the rates 
of death and stroke at 1 and 6 months were lower with CEA than with CAS among patients 
with symptomatic carotid stenosis of 60% or more136. 
Cluster #3 - Carotid endarterectomy 
Cluster #3 was the most durable cluster, containing 71 highly cited references across a 25-
year period from 1989 till 2013. This cluster could also be divided into two stages according 
to the 42 burst references detected. Figure 7 shows the top 5 burst references in each stage. 
In the first stage (1989-2002), the beneficial effect of CEA in different groups of patients 
were evaluated by multicenter randomized controlled trials. Research among patients with 
severe carotid stenosis yielded highly consistent results, while the benefit of CEA in 
asymptomatic patients or symptomatic moderate carotid stenosis patients remained 
controversial146-155. The strongest burst article in this cluster demonstrated that asymptomatic 
patients could benefit from CEA under several restrictions151. New diagnostic tools, 
especially noninvasive imaging of carotid artery stenosis and vulnerable plaques, became the 
next hotspot156-165. 
The second stage (2003-2013) witnessed the emerging of systematic reviews, consensus 
and guidelines. Researches based on real world data defined the boundaries of CEA in 
clinical practice. Pooled data analysis confirmed the beneficial effect of CEA for 
symptomatic moderate and severe carotid stenosis patients, but not for patients with carotid 
near-occlusion166,167. Factors affecting the benefit from CEA mainly included overall rate of 
perioperative stroke and death168, timing of surgery169, operative indications of patients170,171 
and causes of stroke172. In the end of this cluster, the early assessment and the urgent 
treatment of stroke after transient ischemic attack or minor stroke attracted extensive 
interest173-178. 
Cluster #4 - CAS VS CEA 
Cluster #4 was the second largest currently active cluster, with 69 highly cited references 
from 2004 to 2016. Over forty burst references were detected, including 20 RCTs, 10 
guidelines or consensus statements and 7 systematic reviews. This cluster showed an 
interesting phenomenon of the competition between two technologies. 
In the first stage (2004-2010), CEA versus CAS RCTs taked the majority of burst 
articles, in which the perioperative safety and long-term outcomes were the major focuses179-
188. The strongest burst reference in this cluster demonstrated that there were no significant 
differences between the primary outcomes of CEA and CAS, except for a higher risk of 
stroke with CAS and a higher risk of myocardial infarction with CEA during the 
periprocedural period188. Meanwhile, magnetic resonance imaging (MRI) were increasingly 
used in the detection of ischemic brain injury after CAS or CEA189,190. Best practices for the 
management of asymptomatic carotid stenosis patients was another focus in this stage. 
Evidence accumulated from epidemiological studies and therapeutic studies comparing 
medical and surgical treatment191-199. 
The second stage (2011-2016) witnessed the burst of guidelines4,200-204. While the short-
term and long-term outcomes of CAS versus CEA were still controversial205-209, a latest 
guideline downgraded the recommendation for CAS, in certain group of symptomatic 
patients, from Class I to Class IIa based on a meta-analysis of comparative trails4,210. Recent 
studies focused on issues such as subgroup analysis for risk factors identification211,212, MRI 
characterization of carotid plaque10, and the embolic reducing technological optimization in 
CAS213. 
3.2.2 Community 3 – Imaging Techniques in CA 
Cluster #5, #7, #9 and #11 revealed the evolution history of imaging techniques. Cluster #11 
and #7 show the earlier imaging technologies, while #5 and #9 reveal the latest development 
of plaque imaging techniques. 
Cluster #11 - Transcranial doppler sonography 
Cluster #11 was the shortest cluster, containing 13 highly cited references from 1990 till 
1999. The primary focus of this cluster was on the application of transcranial doppler 
sonography in CEA preoperative assessment, intraoperative monitoring and postoperative 
evaluation. At first, the transcranial doppler ultrasound was used to measure the disease 
activity of extracranial carotid artery stenosis in medical and surgical treatments, for its 
ability to detect emboli associated with platelet thrombus and ulcerations in the carotid 
artery214-216. Prospective pilot studies then proved that asymptomatic embolization is an 
independent predictor of future stroke risk in both symptomatic and asymptomatic carotid 
stenosis patients, thus made this technology a potential tool in the definition of a high-risk 
subgroup for CEA 217,218. However, this application was hampered due to the problem of 
sensitivity and specificity in the end of this cluster219,220. 
Cluster #7 - Noninvasive imaging of carotid stenosis 
The primary focus of Cluster #7 (from 1990 to 2001) was on the noninvasive imaging of 
carotid stenosis, primarily in response to the high complication rate of cerebral 
angiography221. Studies in this cluster focused on the standardization of ultrasonic measured 
carotid stenosis and the comparison of angiography with noninvasive methods, including 
duplex ultrasound, computed tomography (CT) angiography and magnetic resonance 
angiography222-235. In the end of this cluster, the predictive value of ultrasonic measured 
hypoechoic carotid plaques on ischemic cerebrovascular events became the next focous236-239. 
Cluster #5 - MRI characterization of carotid plaque 
Cluster #5 was the biggest cluster in Community 3, with 65 highly cited references from 1993 
till 2013. The primary focus of this cluster was on the application of MRI in the 
characterization of carotid plaque. This cluster could be divided into two stages according to 
the 37 burst references detected. 
The first stage was from 1993 to 2005. As the first noninvasive imaging technique that 
allowed the characterization of intraplaque hemorrhage and acute thrombosis240-246, MRI was 
used in the detection of carotid plaques, which in turn led to the classification of 
atherosclerotic lesions247-249. Pathogenic studies based on MRI demonstrated that repeated 
bleeding into the plaque and rupture of the atherosclerotic plaque play an important role in 
the pathogenesis of ischemic stroke caused by carotid artery stenosis250,251. Epidemiological 
studies found the correlations between carotid plaque characteristics and subsequent ischemic 
cerebrovascular events252-256. 
In the second stage (2006-2013), prospective studies proved the association between 
intraplaque hemorrhage (IPH) and cerebrovascular events. IPH, as detected by MRI, predicts 
cerebrovascular events in both symptomatic and asymptomatic carotid stenosis patients9,257-
259. 
Cluster #9 - Positron emission tomography imaging of plaque inflammation 
Cluster #9 was a currently active cluster, containing 23 highly cited references from 2002 till 
2014. The pathophysiology of atherosclerotic lesion had undergone a research renaissance in 
the past decade1,260-262. Positron emission tomography (PET) imaging provided a noninvasive 
measure of atherosclerosis inflammation263, which plays a key role in progression and 
destabilization of atherosclerotic plaque264. The first burst article in this cluster demonstrated 
that atherosclerotic plaque inflammation can be imaged with 18FDG-PET, and symptomatic 
unstable plaques accumulated more 18FDG than asymptomatic lesions164. In recent years, the 
technology of visually monitoring plaque inflammation by 18FDG-PET had been applied in 
the evaluation of therapeutic effectiveness in plaque-based therapy trails265-267. 
3.3 Emerging Trends in CA 
Table 4 lists the 30 articles with transformative potentials from 2012 to 2017. These articles 
had the highest geometric mean of three structural variation variables generated by Citespace. 
We detected three transformative topics in this 6-year period. 
Debate on the expanded application of CAS peaked between 2012 and 2013. The focus 
of the debate was whether the United States Center for Medicare and Medicaid Services 
should extend reimbursement indications for CAS. And it was concluded that the expansion 
would have disastrous health and economic consequences268,269. However, the role of age and 
gender in choosing therapeutic modality gained additional evidence270, and studies are still 
working on the better selection criteria for individually tailored treatment271. 
The role of cIMT for cardiovascular risk stratification was the major transformative topic 
from 2014 to 2015. Population-based studies demonstrated that incremental predictive value 
of cIMT was very limited compared with coronary calcium score272, and cIMT was even no 
longer significantly associated with carotid stenosis after adjustments for plaque and systolic 
blood pressure273. Systolic blood pressure appeared to be a pathological mechanism, 
indirectly affecting cIMT274. Furthermore, limitations still exist in the clearly defined 
threshold value of cIMT and how the presence of high risk cIMT findings in a patient affects 
management decisions275-277. However, a number of carotid imaging parameters had been 
shown to be predictive in the identification of high-risk asymptomatic carotid stenosis 
patients, including ultrasonic measured hypoechoic carotid plaques and MRI detected 
intraplaque hemorrhage6,278. 
 Plaque imaging had become the most concentrated transformative topic since 2016. A 
growing body of evidence shows that noninvasive imaging of the carotid plaque by various 
methods reliably identifies structural correlates of plaque vulnerability and is now used to 
decide on optimal treatment5,11,279-282. 
4. Discussion 
At present, patients with carotid atherosclerotic disease are selected for revascularization or 
medical therapies mainly based on the degree of carotid stenosis and the presence or absence 
of recent ischemic symptoms3,4. However, there is increasing evidence that active, unstable 
plaques in the carotid arteries are more likely to cause symptoms, regardless of stenosis 
severity9,10. Behind these evidences may implicate an important shift in the perception of CA-
mediated CVDs. In our study, we mapped the intellectual structure, evolution history and 
emerging trends of CA through multiple bibliometric analysis based on extensive literature 
available. To the best of our knowledge, this is the first science mapping study on CA. 
We found the hidden patterns in the major specialties and proved that plaque imaging had 
become a converging trend in CA. These interdisciplinary findings are particularly useful for 
sponsors and future researchers to choose the best research topics in CA. It is also important 
for clinical practitioners to be aware of these promising imaging techniques for clinical 
decision-making.  
A specialty of CA may go through 3 stages: the exploration stage, the verification stage 
and the calibration stage (Table 5). In the exploration stage, new tools or therapeutic methods 
will be developed. Exploratory studies, such as cross-sectional studies, case control studies 
and nonrandomized trails, take the majority of influential literatures. In the verification stage, 
high-impact cohort studies or RCTs will dominate. An important task in this stage is the 
standardization of heterogeneous methods. In the calibration stage, the applicable boundaries 
of the new method, as well as competitive theories will be tested. Previously accumulated 
knowledge will be summarized and solidified in form of pooled data analysis, systematic 
reviews, guidelines or consensus. A surrogate biomarker or a novel therapeutic method might 
be routinely applied in clinical practice or widely questioned and declined. The latter may 
continue to contribute to another area of research. 
CA is a multidisciplinary field of study and medical imaging plays a transformative role 
in the revolution of this discipline. Advances in imaging techniques bridged the gaps between 
pathology, epidemiology and clinical practice to form a spiral cycle, thus gradually deepening 
our understanding of the relationship between CA and CVDs. The application of imaging 
techniques - such as ultrasound, CT, MRI and PET - enables researchers to further explore the 
pathogenic mechanisms of CA, evaluate the effects of treatments, predict future 
cardiovascular events and classify patients into different risk groups in clinical practice. The 
standardization of these methods establishes the basis for further systematic analysis and 
clinical application. Pathology, on the other hand, plays an inspiring and explanatory role in 
CA. New pathological hypothesis provides insights into CA. The incomprehensible 
phenomena found in epidemiological and therapeutic studies in turn raise new questions for 
pathological research, thus cyclically promotes our understanding and treatment of carotid 
atherosclerotic diseases. In fact, influential pathological literature often indicates the 
transform of research stages. The shift in scientific research may happen several years before 
the publication of large study results or systematic reviews. Guidelines and consensus are 
only confirmations and manifestations of such shifts. According to the above patterns, we can 
identify the current evolutionary stages of subdomains of CA (Figure 8). 
Effective CA surrogates are essential for clinical decision-making. The benefits, risks and 
costs of prevention strategies must be weighed to choose the best individually tailored 
preventive strategy. In the end of Cluster #2, the shift in perception of cIMT and the emphasis 
on plaque ultrasound measurements occurred almost simultaneously. A similar phenomenon 
appeared in Community 2 that MRI characterization of carotid plaque became a promising 
tool in the competition between CEA and CAS in the end of Cluster #4. On the other hand, 
although early studies on inflammation in atherosclerosis in Cluster #6 had gradually 
declined, carotid plaque inflammation measured by PET allowed this basic study to continue 
in another way. For the first time, plaque imaging became a converging trend in pathology, 
epidemiology and clinical practice in CA. 
5. Limitations 
Our systematic search was comprehensive and carefully conducted but we restricted our 
search strategy to the web of science and we may have missed relevant articles that are not 
accessible in the web of science. However, we extend the object of analysis to the reference 
these articles cited, which totaled 407,473. We believe that these references have covered 
most of the milestones of CA in the past two decades. 
It is relying on the analysis of burst references of major clusters that we identified the 
hidden patterns of CA and the current stages of each sub areas. We therefore may have 
overlooked other influential studies, as well as some important progress made in other related 
but less aggregated branches. However, we must make a trade-off between the main research 
lines and the scattered details. The evolution process of research focuses could be clearly 
reflected by the citation behavior to burst references, thus better maps the main research lines 
of CA. When we focus on the citation behavior of researchers, we could actually “see” the 
cognition changing process of academic communities in a new light, thus avoiding falling 
into the details of bias checking based on limited information. In addition, we used co-word 
analysis and structural variation analysis to help understand the intellectual structure and 
interdisciplinary frontiers of CA, thus providing other perspectives for the interpretation of 
the hidden patterns. 
There have been many theories of scientific change283,284, but it is still difficult to divide 
a particular field of research into distinct stages. Our phased approach to CA is a new attempt 
to quantitatively predict the future directions of medical research. Medical research is a very 
practical subject that new theories and techniques are often constantly tested and refined in 
practice. Therefore, it is difficult to distinguish the boundaries between theoretical research, 
tool development and practical application. However, the patterns of discipline evolution 
could still be observed from the commonness of high-impact literature in different periods. In 
fact, the boundaries between different stages are not strict, and we adopted the important 
milestones as the boundaries of different stages. For instance, the first burst RCT or cohort 
study marks the beginning of the verification stage, while the concentrated publication of 
system review and guidelines is the symbol of calibration stage. 
6. Future perspective 
Our understanding of the mechanism of CA-mediated cardiovascular events is undergoing a 
transition from “luminal narrowing” to “vulnerable plaques”. In the first era, we reduced 
cardiovascular events mainly by curing carotid stenosis. But this paradigm faces enormous 
difficulties in treating patients with asymptomatic or mild to moderate symptomatic carotid 
stenosis, which account for the majority of CA patients. In the second era, we might be able 
to solve this problem by establishing a new treatment and evaluation system based on a series 
of plaque imaging techniques. The intersection of future carotid plaque studies will deepen 
our understanding of the relationship between CA and cardiovascular events, stimulate new 
treatment strategies, and create new diagnostic, assessment and classification tools for 
clinical practice. Major breakthroughs might be expectable in the near future, which may 
have a revolutionary impact on the role of CA in CVDs prevention.  
The rapid accumulation and updating of scientific knowledge poses a great challenge to 
the methodology of systematic review. It has become a major problem, how to understand the 
overall progress and new frontier areas of multiple disciplines. Citespace allows us to 
simultaneously process a huge number of literatures and map the sub-areas of a certain 
discipline through co-citation analysis, thus makes the quantitative exploration of academic 
frontiers possible.  
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Figure 1 The overview of the analytic framework. 
 Figure 2 Co-word network of the major subject categories. Each node represents a common category. The size of a circle represents the co-citation frequency and the 
purple rims of the circles represent the high betweenness centralities. F indicates co-citation frequency; and C, betweenness centrality.  
Figure 3 Timeline view of the co-citation network. Clusters are depicted along horizontal timelines and arranged vertically in descending order according to the size of the 
nodes. Large-sized nodes are highly cited references with more conspicuous labels below. The publication time of each reference is presented by the colour of the 
node. The top-ranked keyword by Log-likelihood ratio test is selected as cluster label.  
 Figure 4 Landscape view of the co-citation network. The co-citation relationship between points is represented by their spatial position. Clusters are naturally formed by the 
spatial aggregation of nodes. The cluster label for the Community 1 is marked green, Community 2, red, and Community 3, blue. Cluster #2, #4 and #9 are the latest active 
clusters dyed in light yellow. 
 Figure 5 The top 5 burst references in each stage of Cluster #0. Cross-sectional studies and case-control studies were marked in green, pharmacological studies in blue, 
imaging studies in yellow, cohort studies in red, and pathological studies in purple. 
  
Figure 6 The top 5 burst references in each stage of Cluster #1. Non-randomized studies were marked in green, imaging studies in yellow, pooled data analysis and 
systematic reviews in grey, randomized controlled trails in red, and guidelines in orange.
 Figure 7 The top 5 burst references in each stage of Cluster #3. Randomized controlled trails were marked in red, pooled data analysis and systematic reviews in grey, and 
guidelines in orange. 
  
 
Figure 8 Evolutionary stages of major specialties in CA. 
Table 1 Basic information of the top 11 significantly aggregated co-citation clusters. 
Cluster ID Size % of the 
network 
Silhouette From To Duration Median Activeness Top 3 keywords selected by Log-likelihood ratio test 
#0 132 15.47  0.911 1989  2005  17  1996 Inactive intima-media thickness; carotid stenosis; ultrasound 
#1 91 10.67  0.866 1990  2008  19  2001 Inactive angioplasty; stent; atherosclerosis 
#2 75 8.79  0.939 2002  2015  14  2009 Active carotid intima-media thickness; cardiovascular disease; rheumatoid arthritis 
#3 72 8.56  0.799 1989  2013  25  1999 Inactive carotid endarterectomy; carotid stenosis; atherosclerosis 
#4 69 8.09  0.873 2004  2016  13  2010 Active carotid endarterectomy; stroke; carotid artery stenting 
#5 65 7.62  0.873 1993  2013  21  2003 Active magnetic resonance imaging; vulnerable plaque; intraplaque hemorrhage 
#6 48 5.63  0.997 1992  2005  14  1998 Inactive chlamydia pneumoniae; inflammation; infection 
#7 46 5.39  0.935 1990  2001  12  1994 Inactive cerebrovascular symptoms; atherosclerosis; duplex 
#8 29 3.40  0.998 1995  2015  21  2006 Active arterial stiffness; pulse wave velocity; augmentation index 
#9 23 2.70  0.975 2002  2014  13  2009 Active positron emission tomography; inflammation; molecular imaging 
#11 13 1.52  0.968 1990  1999  10  1994 Inactive transcranial doppler; cerebral embolism; ultrasonics 
Table 2 Article with the strongest burst in the top 11 clusters. 
Cluster ID  Cluster label No. Mean strength Max strength Article with strongest burst 
#0 intima-media thickness 89  34.63 296.78 Oleary DH, 1999 
#1 angioplasty 53  38.69 223.95 Yadav JS, 2004 
#2 carotid intima-media thickness 52  44.59 250.19 Lorenz MW, 2007 
#3 carotid endarterectomy 46  48.16 255.10 Walker MD, 1995 
#4 carotid endarterectomy 42  51.21 265.28 Brott TG, 2010 
#5 magnetic resonance imaging 37  31.10 64.38 Takaya N, 2006 
#6 chlamydia pneumoniae 30  34.87 239.42 Ross R, 1999 
#7 cerebrovascular symptoms 22  20.85 46.87 Mathiesen EB, 2001 
#8 arterial stiffness 20  35.90 90.93 Laurent S, 2006 
#9 positron emission tomography 10  26.66 50.25 Libby P, 2011 
#11 transcranial doppler 10  16.89 24.27 Eliasziw M, 1994 




Begin End Duration (1997-2017) Strength 
Taylor DW, 1991, New Engl J Med146 1997 1999 ▃▃▃▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂ 171.36  #3 
Warlow C, 1991, Lancet148 1998 1999 ▂▃▃▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂ 103.49  #3 
Hobson RW, 1993, New Engl J Med149 1997 2001 ▃▃▃▃▃▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂ 84.50  #3 
Walker MD, 1995, Jama151 1998 2003 ▂▃▃▃▃▃▃▂▂▂▂▂▂▂▂▂▂▂▂▂▂ 255.10  #3 
Diethrich EB, 1996, J Endovasc Surg119 1998 2004 ▂▃▃▃▃▃▃▃▂▂▂▂▂▂▂▂▂▂▂▂▂ 67.50  #1 
Yadav JS, 1997, Circulation123 1998 2005 ▂▃▃▃▃▃▃▃▃▂▂▂▂▂▂▂▂▂▂▂▂ 82.74  #1 
Barnett HJM, 1998, New Engl J Med154 2000 2006 ▂▂▂▃▃▃▃▃▃▃▂▂▂▂▂▂▂▂▂▂▂ 190.07  #3 
Farrell B, 1998, Lancet153 2000 2006 ▂▂▂▃▃▃▃▃▃▃▂▂▂▂▂▂▂▂▂▂▂ 154.53  #3 
Brown MM, 2001, Lancet132 2003 2009 ▂▂▂▂▂▂▃▃▃▃▃▃▃▂▂▂▂▂▂▂▂ 118.24  #1 
Roubin Gs, 2001, Circulation285 2003 2008 ▂▂▂▂▂▂▃▃▃▃▃▃▂▂▂▂▂▂▂▂▂ 85.32  #1 
Rothwell PM, 2003, Lancet166 2004 2011 ▂▂▂▂▂▂▂▃▃▃▃▃▃▃▃▂▂▂▂▂▂ 96.43  #3 
Yadav JS, 2004, New Engl J Med135 2005 2012 ▂▂▂▂▂▂▂▂▃▃▃▃▃▃▃▃▂▂▂▂▂ 223.95  #1 
Halliday A, 2004, Lancet191 2005 2012 ▂▂▂▂▂▂▂▂▃▃▃▃▃▃▃▃▂▂▂▂▂ 179.10  #4 
Rothwell PM, 2004, Lancet169 2005 2012 ▂▂▂▂▂▂▂▂▃▃▃▃▃▃▃▃▂▂▂▂▂ 80.80  #3 
Hobson RW, 2004, J Vasc Surg286 2006 2012 ▂▂▂▂▂▂▂▂▂▃▃▃▃▃▃▃▂▂▂▂▂ 64.63  #1 
Mas J, 2006, New Engl J Med136 2007 2014 ▂▂▂▂▂▂▂▂▂▂▃▃▃▃▃▃▃▃▂▂▂ 138.71  #1 
Ringleb PA, 2006, Lancet180 2008 2014 ▂▂▂▂▂▂▂▂▂▂▂▃▃▃▃▃▃▃▂▂▂ 101.38  #4 
Gurm HS, 2008, New Engl J Med182 2009 2017 ▂▂▂▂▂▂▂▂▂▂▂▂▃▃▃▃▃▃▃▃▃ 69.79  #4 
Eckstein HhH 2008, Lancet Neurol181 2009 2017 ▂▂▂▂▂▂▂▂▂▂▂▂▃▃▃▃▃▃▃▃▃ 67.31  #4 
Abbott AL, 2009, Stroke199 2011 2017 ▂▂▂▂▂▂▂▂▂▂▂▂▂▂▃▃▃▃▃▃▃ 65.65  #4 
Liapis CD, 2009, Eur J Vasc Endovasc287 2010 2017 ▂▂▂▂▂▂▂▂▂▂▂▂▂▃▃▃▃▃▃▃▃ 64.03  #4 
Brott TG, 2010, New Engl J Med188 2011 2017 ▂▂▂▂▂▂▂▂▂▂▂▂▂▂▃▃▃▃▃▃▃ 265.28  #4 
Ederle J, 2010, Lancet187 2011 2017 ▂▂▂▂▂▂▂▂▂▂▂▂▂▂▃▃▃▃▃▃▃ 133.53  #4 
Halliday A, 2010, Lancet194 2011 2017 ▂▂▂▂▂▂▂▂▂▂▂▂▂▂▃▃▃▃▃▃▃ 69.32  #4 
Kernan WN, 2014, Stroke4 2015 2017 ▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▃▃▃ 62.81  #4 
Table 4 Articles with transformative potential published in recent years (2012–2017). 
Citing Articles F △M △C ILs TLs 
Fent Gj, 2017, Ann Rheum Dis288 5 1.36 0.21 1 2 
Maier A, 2017, Atherosclerosis279 0 0.94 0.02 0 2 
Chowdhury MM, 2017, Curr Cardiovasc Imag280 0 0.93 0 0 2 
Sun J, 2016, Neuroimag Clin N Am5 2 2.82 0.04 0 5 
Bonati Lh, 2016, Neuroimag Clin N Am282 5 1.47 0.03 1 2 
Brinjikji W, 2016, J Neurosurg11 31 0.95 0.04 0 2 
Atchaneeyasakul K, 2016, Interv Neurol289 1 0.75 0.51 0 1 
Sakamoto S, 2016, J Neurointerv Surg281 2 0.71 0.01 0 1 
Calvet D, 2016, Int J Stroke290 5 0.7 0.02 0 1 
Vlachopoulos C, 2015, Atherosclerosis276 182 2.16 0.12 0 6 
Polak JF, 2015, J Am Soc Echocardiog277 7 1.33 0.01 0 3 
Paraskevas Ki, 2014, Stroke6 32 1.84 0.25 0 3 
Naylor Ar, 2014, Eur J Vasc Endovasc278 33 1.12 0.07 0 2 
Martinsson A, 2014, Arterioscl Throm Vas273 13 0.85 0 0 2 
Lee Cj, 2014, Yonsei Med J275 7 0.85 0 0 2 
Dratva J, 2014, Swiss Med Wkly274 4 0.85 0 0 2 
Frerix M, 2014, Arthritis Res Ther291 24 0.75 0.01 1 2 
Ferket BS, 2014, Plos One272 11 0.75 0.01 1 2 
Giannopoulos S, 2013, Neurol Sci270 10 1.32 0.04 0 2 
Eckstein Hh, 2013, Dtsch Arztebl Int271 56 1.32 0.04 0 2 
Cambria Rp, 2012, J Vasc Surg268 3 3.29 0.08 2 6 
Abbott Al, 2012, Brain Behav269 0 3.29 0.08 2 6 
Doig D, 2012, Annu Rev Med292 4 2.02 0.09 2 4 
Koennecke HC, 2012, Vasa293 4 1.5 0.04 1 3 
Touze E, 2012, Curr Vasc Pharmacol294 7 1.33 0.01 0 2 
Kerekes G, 2012, Nat Rev Rheumatol295 66 1.33 0.01 0 5 
Habersberger J, 2012, Curr Opin Cardiol296 4 1.33 0.01 0 2 
Tulip HH, 2012, J Vasc Surg297 9 1.26 0 0 2 
Kakisis JD, 2012, Eur J Vasc Endovasc298 43 1.26 0 0 2 
Bonati LH, 2012, Cochrane Db Syst Rev210 26 1.24 0.05 1 2 
F=Frequency; △M=△Modularity; △C=△Centrality; ILs=Incremental Links; TLs=Transformative Links.
Table 5 The three evolutionary stages of CA 
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